Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792687 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
A Phase 1 study, sponsored by Aragon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01792687 is a Phase 1 study that has completed, run by Aragon Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT01792687, a Phase 1 study, has completed, sponsored by Aragon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
Interventions
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG ARN-509
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-02-05 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01792687
The ClinicalTrials.gov registry entry for NCT01792687 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT01792687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01792687 about?
NCT01792687 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate". This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
What is the current status of trial NCT01792687?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-02-05. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT01792687?
The interventions under investigation include: Prednisone (DRUG), Abiraterone acetate (DRUG), ARN-509 (DRUG).
Who is sponsoring clinical trial NCT01792687?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.